One of the two planetary cornerstone missions of the European Space Agency is the Rosetta mission to comet 67P/Churyumov-Gerasimenko. Rosetta is a rendezvous mission with a comet nucleus, which combines an Orbiter with a Lander. It will monitor the evolution of the comet nucleus and the coma as a function of increasing and decreasing solar flux input along the comet’s pre- and post-perihelion orbit. Different instrumentations will be used in parallel, from multi-wavelength spectrometry to in-situ measurements of coma and nucleus composition and physical properties. Rosetta will go in orbit around the nucleus of its target comet 67P/Churyumov-Gerasimenko, when it is still far from the Sun and accompany the comet along its way to perihelion and beyond. In addition the Rosetta Lander Philae will land on the nucleus surface, before the comet is too active to permit such a landing (i.e. at around r = 3 AU) and examine the surface and subsurface composition of the comet nucleus as well as its physical properties.
No takes yet. Share an insight, caveat, or question.
R. Schulz (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: